# Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

> **NCT02007005** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abnoba Gmbh** · enrollment: 37 (actual)

## Conditions studied

- Superficial Bladder Cancer

## Interventions

- **DRUG:** abnobaVISCUM Fraxini

## Key facts

- **NCT ID:** NCT02007005
- **Lead sponsor:** Abnoba Gmbh
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2012-02
- **Final completion:** 2013-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02007005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02007005, "Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02007005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*